Products
Platform
Research
Market
Learn
Compare HDFC Pharma And Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.07 | 1.88 |
NAV | ₹17.86 | ₹41.47 |
Fund Started | 14 Sep 2023 | 25 Jun 2018 |
Fund Size | ₹1786.18 Cr | ₹5727.59 Cr |
Exit Load | Exit load of 1%, if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
4.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.07
1.88
NAV
₹17.86
₹41.47
Fund Started
14 Sep 2023
25 Jun 2018
Fund Size
₹1786.18 Cr
₹5727.59 Cr
Exit Load
Exit load of 1%, if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 23.76% | 17.05% |
3 Year | - | 29.50% |
5 Year | - | 23.89% |
1 Year
23.76%
17.05%
3 Year
-
29.50%
5 Year
-
23.89%
Holding Analysis
Equity | 97.93% | 96.45% |
Cash | 2.07% | 3.55% |
Equity
97.93%
96.45%
Cash
2.07%
3.55%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.68% |
Divi's Laboratories Ltd. | 10.06% |
Cipla Ltd. | 6.87% |
Lupin Ltd. | 5.60% |
Glenmark Pharmaceuticals Ltd. | 5.53% |
Ipca Laboratories Ltd. | 4.47% |
Torrent Pharmaceuticals Ltd. | 3.83% |
Krishna Institute of Medical Sciences Ltd | 3.71% |
Eris Lifesciences Ltd. | 3.60% |
Aster DM Healthcare Ltd. | 3.59% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.23% |
Divi's Laboratories Ltd. | 8.95% |
Dr. Reddy's Laboratories Ltd. | 8.92% |
Cipla Ltd. | 7.75% |
Aurobindo Pharma Ltd. | 6.06% |
Biocon Ltd. | 5.02% |
Mankind Pharma Ltd. | 4.20% |
Alkem Laboratories Ltd. | 4.01% |
Lupin Ltd. | 3.79% |
Gland Pharma Ltd. | 3.57% |
Fund Manager
Name | Dhruv Muchhal | Dharmesh Kakkad |
Start Date | 14 Sep 2023 | 23 Feb 2021 |
Name
Dhruv Muchhal
Dharmesh Kakkad
Start Date
14 Sep 2023
23 Feb 2021
About Fund
Description | The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 14 Sep 2023 | 25 Jun 2018 |
Description
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
14 Sep 2023
25 Jun 2018
